Aspen’s offer to cut prices of cancer drugs allows it to avoid EU fine
The EU executive is concerned that Aspen may have charged excessive prices for drugs mainly used to treat leukaemia and other haematological cancers
10 February 2021 - 17:00
Brussels — Aspen Pharmacare warded off a possible hefty EU antitrust fine after regulators accepted the pharmaceutical company’s offer to cut cancer drug prices in Europe by about two-thirds, in a landmark case aimed at deterring excessive prices.
In the past decade, the European Commission has cracked down on the pharmaceutical industry for pay-for-delay deals between brand name companies and their generic rivals, while shying away from excessive pricing cases...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.